Industry Updates from the Field of Stem Cell Research and Regenerative Medicine in May 2020
2020; Future Medicine; Volume: 15; Issue: 9 Linguagem: Inglês
10.2217/rme-2020-0090
ISSN1746-076X
Autores Tópico(s)3D Printing in Biomedical Research
ResumoRegenerative MedicineVol. 15, No. 9 Industry NewsIndustry updates from the field of stem cell research and regenerative medicine in May 2020Dusko Ilic & Mirjana LiovicDusko Ilic *Author for correspondence: E-mail Address: dusko.ilic@kcl.ac.ukhttps://orcid.org/0000-0003-1647-0026Stem Cell Laboratories, Guy's Assisted Conception Unit, Department of Women & Children's Health, Faculty of Life Sciences & Medicine, King's College London, London, UK & Mirjana Liovic https://orcid.org/0000-0001-8045-7868Medical Center for Molecular Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, SloveniaPublished Online:27 Jul 2020https://doi.org/10.2217/rme-2020-0090AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleAbstractLatest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in May 2020.Keywords: industryregenerative medicinestem cellsReferences1. Business Wire. EdiGene and Immunochina announce research and development collaboration to develop allogeneic CAR-T therapy for cancer (2020). https://www.businesswire.com/news/home/20200527005319/en/EdiGene-Immunochina-Announce-Research-Development-Collaboration-DevelopGoogle Scholar2. AgeX Therapeutics. AgeX Therapeutics and Sernova to collaborate to engineer universal locally immune protected cell therapies for Type I diabetes and hemophilia A (2020). http://www.agexinc.com/investors-media/single-news-story/?id=6801Google Scholar3. Cell and Gene Therapy Catapult. CiRA Foundation and the Cell and Gene Therapy Catapult set to launch new stem cell collaborative research (2020). https://ct.catapult.org.uk/news-media/general-news/press-release-cira-foundation-and-cgt-catapult-launch-collaborationGoogle Scholar4. Hesperos. Hesperos Human-on-a-Chip® system used to model preclinical stages of Alzheimer's disease and mild cognitive impairment (2020). https://hesperosinc.com/hesperos-human-on-a-chip-system-models-preclinical-stages-of-alzheimers/Google Scholar5. Caneus J, Akanda N, Rumsey JW et al. A human induced pluripotent stem cell-derived cortical neuron human-on-a chip system to study Aβ42 and tau-induced pathophysiological effects on long-term potentiation. Alzheimers Dement. (NY) 6(1), e12029 (2020).Medline, Google Scholar6. Lineage Cell Therapeutics. Lineage Cell Therapeutics reports new data with OpRegen for the treatment of Dry AMD with geographic atrophy (2020). https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-reports-new-data-opregen-treatment-dryGoogle Scholar7. Gamida Cell. Gamida Cell Announces positive topline data from Phase III clinical study of omidubicel in patients with high-risk hematologic malignancies (2020). https://investors.gamida-cell.com/node/7236/pdfGoogle Scholar8. Allogene Therapeutics. Allogene Therapeutics, with collaborator Servier, reports positive results from its Phase 1 alpha study of ALLO-501 in relapsed/refractory non-hodgkin lymphoma at The American Society of Clinical Oncology Annual Meeting (2020). https://ir.allogene.com/node/7416/pdfGoogle Scholar9. Poseida Therapeutics. Poseida Therapeutics announces dosing of first patient in Phase I clinical trial of P-PSMA-101 autologous Car-T for metastatic castration-resistant prostate cancer (2020). https://poseida.com/poseida-therapeutics-announces-dosing-of-first-patient-in-phase-1-clinical-trial-of-p-psma-101-autologous-car-t-for-metastatic-castration-resistant-prostate-cancer/Google Scholar10. CARsgen Therapeutics. CARsgen Therapeutics receives IND clearance from the US FDA for CT041 CLDN18.2-CAR-T cells (2020). http://www.carsgen.com/public/uploads/files/202005/554eb25ea4ba0b06.pdfGoogle Scholar11. Jiang H, Shi Z, Wang P et al. Claudin18.2 - specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J. Natl Cancer Inst. 111(4), 409–418 (2019).Crossref, Medline, Google Scholar12. Cynata Therapeutics. Cynata receives ethics approval to commence clinical trial in COVID-19 and clinical development update (2020). http://files.cynata.com/571/20.05.08.Ethics-Approval-to-Commence-Clinical-Trial-in-COVID-19.pdfGoogle Scholar13. Fate Therapeutics. Fate Therapeutics announces FDA clearance of IND application for FT538, first CRISPR-edited, iPSC-derived cell therapy (2020). https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-fda-clearance-ind-application-ft538Google Scholar14. Lineage Cell Therapeutics. Lineage Cell Therapeutics announces early exercise of option with Cancer Research UK for immuno-oncology cell therapy program (2020). https://investor.lineagecell.com/node/20401/pdfGoogle Scholar15. NantKwest. NantKwest announces FDA authorization of IND application for mesenchymal stem cell product for the treatment of severe COVID-19 patients (2020). https://nantkwest.com/nantkwest-announces-fda-authorization-of-ind-application-for-mesenchymal-stem-cell-product-for-the-treatment-of-severe-covid-19-patients/Google Scholar16. NantKwest. Be The Match BioTherapies and NantKwest announce collaboration to accelerate development of cell therapy to prevent COVID-19 deaths (2020). https://nantkwest.com/be-the-match-biotherapies-and-nantkwest-announce-collaboration-to-accelerate-development-of-cell-therapy-to-prevent-covid-19-deaths/Google Scholar17. Pluristem. U.S. FDA clears Pluristem's IND application for Phase II COVID-19 study (2020). http://www.pluristem.com/wp-content/uploads/2020/05/FDA-Clearance-COVID-19-FINAL.pdfGoogle Scholar18. Pluristem. Pluristem reports preliminary data from its COVID-19 compassionate use program, treating seven patients with acute respiratory failure (2020). http://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdfGoogle Scholar19. PR Newswire. FDA approves COVID-19 trial after successful emergency use of umbilical stem cells from RESTEM (2020). http://www.prnewswire.com/news-releases/fda-approves-covid-19-trial-after-successful-emergency-use-of-umbilical-stem-cells-from-restem-301059158.htmlGoogle Scholar20. Medpace. Lessons learned in emerging cell and gene therapies: a holistic approach to clinical development (2020). http://www.medpace.com/wp-content/uploads/2020/05/Whitepaper-Lessons-Learned-in-emerging-cell-and-gene-therapies.pdfGoogle Scholar21. Gamida Cell. Gamida Cell announces full exercise of underwriters' option to purchase additional shares (2020). https://investors.gamida-cell.com/node/7306/pdfGoogle ScholarFiguresReferencesRelatedDetails Vol. 15, No. 9 Follow us on social media for the latest updates Metrics Downloaded 35 times History Received 23 June 2020 Accepted 3 July 2020 Published online 27 July 2020 Published in print September 2020 Information© 2020 Future Medicine LtdKeywordsindustryregenerative medicinestem cellsFinancial & competing interests disclosureThe author Dusko Ilic has received an honorarium from Future Science Group for the contribution of this work. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)